Angiogenesis: Endostatin Protein Immunoassay Kit
- View SourceThursday September 3, 7:33 am Eastern Time
Company Press Release
EntreMed Inc. and
CytImmune Sciences Inc.
Announce Product Launch of
Endostatin Protein Immunoassay Kit
ROCKVILLE, Md.--(BW HealthWire)--Sept. 3, 1998--EntreMed Inc.
(Nasdaq:ENMD - news) and CytImmune Sciences Inc. Thursday
announced the product launch of the Endostatin Protein ACCUCYTE
Immunoassay Kit developed collaboratively by the companies.
The patented ACCUCYTE kit is the first commercially available immunoassay
kit for the detection of human Endostatin protein in biological fluids, such as
blood. A naturally occurring fragment of collagen XVIII, Endostatin protein
was discovered in 1996 in the laboratory of Dr. Judah Folkman at Children's
Antiangiogenic agents such as Endostatin starve tumors to death by
blocking the growth of blood vessels that supply nutrients necessary for their
proliferation. In preclinical studies in mice, Endostatin protein has proven to
be a potent antiangiogenic agent by repeatedly inhibiting the growth of
metastatic and primary cancerous tumors with no noted drug resistance or
Dr. Lawrence Tamarkin, president and chief executive officer for CytImmune
Sciences, commented on the product launch, ``Scientists worldwide now
have a new research tool to accurately measure Endostatin in fluids from
patients with cancer and cardiovascular disease.
``The Endostatin kit is part of CytImmune's ACCUCYTE assay product line
designed to measure angiogenic factors and garner critical data which may
be used for future diagnostic applications.''
CytImmune Sciences developed the Endostatin antibody and the critical
components of the ACCUCYTE Immunoassay kit. EntreMed supplied
purified recombinant Endostatin for the generation of the antibody and for
use as the kit standard against which unknown Endostatin protein is
measured. CytImmune Sciences is initially selling the kit for research use
only, and EntreMed will receive royalties from those sales.
Dr. John W. Holaday, EntreMed chairman, president and chief executive
officer, commented on the ACCUCYTE Immunoassay Kit, ``This new assay
will allow researchers to detect human Endostatin protein and to understand
its potential association with diseases such as cancer and blindness.
``The kit also serves as an important method of monitoring the production
lots and pharmacological profile of Endostatin as we continue to develop
this important product candidate.''
EntreMed holds the commercial rights to Endostatin protein and is currently
preparing for the commencement of human clinical trials in 1999.
College Park, Md.-based CytImmune Sciences is a privately held company
founded in 1988. The company patented its ACCUCYTE product line in
1996 and has commercialized 25 immunoassay kits.
After receiving an initial round of funding in 1997, the company is
collaborating with research entities worldwide to explore new platform
technologies including targeted drug delivery systems, methods for safe
delivery of cytokines for immunotherapeutic regimens, gene therapy and
For further information, visit the CytImmune Sciences Web site at
Rockville-based EntreMed, the Angiogenesis Company, is a leader in the
field of antiangiogenesis research, which involves the inhibition of abnormal
blood vessel growth recently associated with a broad range of diseases.
The company's strategy is to accelerate development of its core
technologies through collaborations and sponsored research programs with
university medical departments, pharmaceutical companies and government
EntreMed has a strategic partnership with Bristol-Myers Squibb Co.
[NYSE:BMY - news] to further the preclinical and clinical development of
Angiostatin protein and thalidomide analogs.
For further information, visit the EntreMed Web site at www.entremed.com.
Statements herein that are not descriptions of historical facts are
forward-looking and subject to risk and uncertainties. Actual results could
differ materially from those currently anticipated due to a number of factors,
including those set forth in the company's Securities and Exchange
Commission filings under ``Risk Factors,'' including risks relating to the early
stage of products under development; uncertainties
relating to clinical trials; dependence on third parties; future capital needs;
and risks relating to the commercialization, if any, of the company's proposed
products (such as marketing, safety, regulatory, patent, product liability,
supply, competition and other risks).
EntreMed Inc., Rockville
Mary P. Sundeen, 301/738-2490
CytImmune Sciences Inc., College Park
Lawrence Tamarkin, Ph.D., 301/445-4220